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J PIntroduction: In an effort to reduce methicillin-resistant Staphylococcus aureus (MRSA) trans-
mission through universal screening and isolation, the Department of Veterans Affairs (VA)
launched the National MRSA Prevention Initiative in October 2007. The objective of this analysis
was to quantify the budget impact and cost effectiveness of this initiative.
Methods: An economic model was developed using published data on MRSA hospital-acquired
infection (HAI) rates in the VA from October 2007 to September 2010; estimates of the costs of
MRSA HAIs in the VA; and estimates of the intervention costs, including salaries of staff members
hired to support the initiative at each VA facility. To estimate the rate of MRSA HAIs that would
have occurred if the initiative had not been implemented, two different assumptions were made: no
change and a downward temporal trend. Effectiveness was measured in life-years gained.
Results: The initiative resulted in an estimated 1,4662,176 fewer MRSA HAIs. The initiative itself
was estimated to cost $207 million during this 3-year period, while the cost savings from prevented
MRSA HAIs ranged from $27 million to $75 million. The incremental cost-effectiveness ratios
ranged from $28,048 to $56,944/life-years. The overall impact on the VA’s budget was $131$179
million.
Conclusions:Wide-scale implementation of a national MRSA surveillance and prevention strategy
in VA inpatient settings may have prevented a substantial number of MRSA HAIs. Although the
savings associated with prevented infections helped offset some but not all of the cost of the
initiative, this model indicated that the initiative would be considered cost effective.
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an open access article under the CC BY-NCIntroductionStaphylococcus aureus, a bacterium carried in thenares of up to 40% of healthy individuals, cancause a wide range of clinically signiﬁcant infec-
tions.1-3 Among adults colonized with methicillin-
resistant S. aureus (MRSA), a substantial proportion
(18%33%) will go on to develop infections such as
pneumonia, soft tissue infections, or bloodstream infec-
tions.4-8 Though MRSA infections are a signiﬁcant
contributor to morbidity, mortality, and healthcare
utilization in the U.S.,9 the observed incidence in hospital
settings has decreased steadily since 2005.10,11 This
decline may be due to increased attention to infection
prevention.ournal of Preventive Medicine  Published by Elsevier Inc. This is
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nelson et al / Am J Prev Med 2016;50(5S1):S58–S65 S59In October 2007, in an effort to reduce transmission of
MRSA in hospitals, the Department of Veterans Affairs
(VA) implemented the MRSA Prevention Initiative.12
This initiative consisted of a bundle that included:1.Mauniversal nasal surveillance for MRSA;
2. contact precautions for patients whose nasal test for
MRSA was positive;
3. improved hand hygiene efforts; and
4. an increased emphasis on infection control being the
responsibility of all healthcare workers.
Several recently published studies have shown that
MRSA hospital-acquired infections (HAIs) decreased
signiﬁcantly after the implementation of the
initiative.12,13
Cost-effectiveness analysis (CEA) is a common ana-
lytic tool used to evaluate the costs and clinical beneﬁts of
two or more strategies. Several CEAs have been pub-
lished demonstrating that the MRSA Prevention Initia-
tive components are cost saving or cost effective,
including universal nasal surveillance, contact precau-
tions, and improved hand hygiene.14 Budget impact
analyses (BIAs), on the other hand, are complementary
to but slightly different from CEAs. Whereas the purpose
of a CEA is to examine the tradeoff between costs and
beneﬁts at a per-patient level, BIAs are designed to
examine the expected expenditures a healthcare system
might face after implementation of a new intervention.15
The objective of this study was to conduct both a BIA and
a CEA of the VA MRSA Prevention Initiative.
Methods
Budget Impact Model
The budget impact model compared the observed rate of MRSA
HAIs that occurred in the VA nationwide after the implementa-
tion of the initiative with the estimated rate of MRSA HAIs that
would have occurred if the initiative had not been implemented
(Appendix Figure 1, available online). The expected rate of MRSA
HAIs in the absence of the intervention was estimated under two
possible scenarios. First, it was assumed that the MRSA HAI rate
would have remained ﬂat (straight line). Second, there is evidence
to suggest that the rate of MRSA HAIs was decreasing across the
U.S. leading up to the MRSA Prevention Initiative, and that it
continued to decline after its implementation.10 Therefore, it was
also assumed that, without the intervention, the MRSA HAI rate in
the VA would have decreased at the same rate as it did outside
the VA.
Both the observed rate of MRSA HAIs and the hypothetical,
counterfactual rates were applied to the 1,746,690 admissions that
occurred in the 153 VA hospitals between October 2007 and
September 2010 to generate estimates of the total number of
MRSA HAIs under each scenario. The difference between the
counterfactual number of MRSA HAIs and the observed numbery 2016of MRSA HAIs was the estimated number of infections prevented
because of the initiative. Estimates of the cost of MRSAHAIs in the
VA were then applied to the counts of prevented infections to
generate aggregate cost savings due to prevented infections. The
ﬁnal budget impact calculations consisted of comparing the cost
savings from the initiative with the estimated costs of implement-
ing the initiative.
Cost-Effectiveness Analysis
A decision analytic model (Appendix Figure 2, available online)
was constructed using TreeAgePro 2013, R1.0. In addition to the
cost estimates generated from the budget impact model, the
effectiveness outcome in the CEA was life-years (LYs) gained.
The costs and LYs gained were combined to construct incremental
cost-effectiveness ratios (ICERs), a commonly used metric in
CEAs, which was calculated by taking the ratio of the difference
in costs and the difference in LYs between the initiative and the no
initiative scenarios. In this analysis, the ICERmeasures the amount
of money spent by the VA for the MRSA Prevention Initiative for
each additional year of patient life that resulted from the initiative.
Finally, a probabilistic sensitivity analysis was conducted by
performing 10,000 Monte Carlo simulations. Cost parameters
were assumed to have γ distributions and probability parameters
were assumed to have β distributions.
Data
The source for observable rates of MRSA HAIs in the VA was a
2011 paper by Jain et al.12 That study documented the decline in
MRSA HAI rates using data on infections entered into an
electronic database maintained by the VA Inpatient Evaluation
Center by the MRSA prevention coordinator at each VA facility. In
that study, HAIs were reported separately by intensive care unit
(ICU) or non-ICU. In the current study, it was assumed that 10.9%
of patients admitted to a VA hospital are admitted to the ICU.16
In two recent studies, the authors estimated the attributable cost
of MRSA HAIs from the perspective of the VA (Table 1). The ﬁrst
paper estimated the excess cost incurred prior to discharge from
the hospital17 and the second estimated the readmission and
pharmacy costs attributable to an MRSA HAI during the 1-year
period following discharge from the hospital.18 In both instances,
inpatient costs were separated into ﬁxed and variable costs, a
distinction that is important when attempting to estimate the
expenses that could be saved by preventing HAIs.30 Fixed costs are
those that are associated with long-term obligations and are
difﬁcult to change in the short run. Variable costs can be avoided
in the short run and therefore represent expenditures that could be
saved if an HAI is prevented.
Estimates of the costs of the initiative included those associated
with screening all admitted patients, the use of gloves and gowns
for patients placed on contact precautions, and salaries of a MRSA
prevention coordinator and 50% of a laboratory technician for
each facility. The role of the MRSA prevention coordinator was to
manage the implementation of the initiative, collect data, assist
healthcare providers, and develop strategies for overcoming any
challenges that arose. It was assumed that this position was ﬁlled
by a registered nurse and the estimated salary was obtained from
the U.S. Bureau of Labor Statistics.22 Polymerase chain reaction
tests for MRSA were assumed to cost $25 per test.19,20 Gloves and
Nelson et al / Am J Prev Med 2016;50(5S1):S58–S65S60gowns cost $0.07 and $0.80 each,21 respectively, and patients on
contact precautions were visited by nurses 20 times and by doctors
four times per day.24-26 In addition to the cost of the supplies, the
cost of the time required to don the gloves and gowns on each use
was also included (2 minutes).23 Finally, the model included the
cost of educational materials, such as literature on the importance
of hand hygiene and contact precautions in reducing transmission
of MRSA in the hospital.
For the CEA, the mean age of a patient admitted to a VA
hospital was assumed to be 50 years and the life expectancy of
these individuals was assumed to be 78.8 years.27 Outcomes
occurring in future time periods but related to the initial hospital
stay were discounted at a rate of 3%. Therefore, patients who did
not die from MRSA HAIs were assumed to gain 20.2 discounted
LYs. The absolute risk of predischarge mortality in patients with
MRSAHAI was assumed to be 10.1%. From a previously published
study,29 the authors found a hazard ratio of 1.46 associated with
mortality in patients with MRSA compared with those without
MRSA HAI during the 1-year post-discharge period. The 1-year
probability of death for individuals aged 50 years (0.0042) was
obtained from the actuarial tables from the U.S. Social Security
Administration.28 This probability was converted into a rate,
multiplied by the death hazard ratio for patients with MRSA
HAI compared with patients without MRSA HAI, then converted
back to a probability to obtain the 1-year post-discharge proba-
bility of death for patients with MRSA HAI. Because all costs
associated with the initial hospital stay were assumed to occur in
the ﬁrst year, costs were not discounted. Costs were converted to
2013 U.S. dollars.Results
Figure 1 depicts the number of MRSA HAIs calculated
based on rates reported in 2011 by Jain and colleagues12
during ﬁscal year 20082010, as well as the hypothetical
number of HAIs that would have occurred in non-ICU
and ICU settings had the MRSA Prevention Initiative not
been implemented. Under the straight-line assumption
of the rate of MRSA HAIs, the initiative resulted in anFigure 1. Number of MRSA HAIs with and without the VA MRSA
HAI, hospital-acquired infection; ICU, intensive care unit; MRSA, methicillin-restimated 943 fewer non-ICU MRSA HAIs and 1,234
fewer MRSA HAIs in the ICU over the 3-year time
period. This equates to an absolute risk reduction of 0.12
and 0.86 MRSA HAIs per 1,000 patient-days, respec-
tively. If the rate of MRSA HAIs had taken a downward
trend as seen elsewhere in the U.S., the initiative would
have led to approximately 517 fewer non-ICU MRSA
HAIs (absolute risk reduction, 0.07 per 1,000 patient-
days) and 949 fewer MRSA HAIs in the ICU (absolute
risk reduction, 0.66 per 1,000 patient-days).
The estimated total costs of the initiative are depicted
in Appendix Figure 3 (available online). More than one
third of the $206.5 million costs of the initiative ($83.2
million) were due to screening of patients on hospital
admission, ward transfer, or discharge from the facility.
Salaries for the MRSA prevention coordinators assigned
to each hospital accounted for 20% ($41.2 million) and
laboratory technicians accounted for 7% ($15.0 million)
of the costs of the initiative. Including the MRSA
prevention coordinator and laboratory technician sal-
aries into the cost calculations is one of the unique
aspects of this study.
The cost savings due to MRSA HAIs prevented as a
result of the initiative depended on the assumptions of
the number of MRSA HAIs that would have occurred
without the initiative. The overall cost savings were $75.3
million and $50.7 million for total costs and $40.1 million
and $27.0 million for variable costs under the assumption
of a straight-line and downward trend in MRSA HAIs,
respectively (Table 2).
The overall budget impact of the VA’s MRSA Pre-
vention Initiative is shown in Table 3. When focusing on
variable costs, the model indicated that the initiative cost
the VA $166.4 million over the 3-year period if the rate of
MRSA HAIs had remained ﬂat without the initiative and
$179.5 million if the rate of MRSA HAIs had shown aPrevention Initiative.
esistant Staphylococcus aureus; VA, Department of Veterans Affairs.
www.ajpmonline.org
Table 1. Input Parameters for BIA and CEA Model
Input Value Source
Admission-related parameters
No. of admissions/year in VA 582,230 Jain (2012)12
Proportion of VA inpatients admitted to ICU 0.109 Chen (2016)16
ICU patient-days per month 39,783 Jain (2011)
Non-ICU patient-days per month 212,298 Jain (2011)
MRSA screening tests (n)
Performed on admission
FY2008 585,200 Jain (2011)
FY2009 637,500 Jain (2011)
FY2010 644,500 Jain (2011)
Performed on transfer or discharge
FY2008 447,500 Jain (2011)
FY2009 506,500 Jain (2011)
FY2010 507,500 Jain (2011)
HAI MRSA rates (per 1,000 patient-days)
ICU, baseline 1.64 Jain (2011)
Non-ICU, baseline 0.46 Jain (2011)
Monthly change if no initiative, downward
trend assumption, %
0.8 Dantes (2013)10
Costs, U.S.$
MRSA HAI
Pre-discharge variable 12,272 Nelson (2015)17
Pre-discharge total 24,015 Nelson (2015)17
Post-discharge inpatient variable 5,826 Nelson (2015)18
Post-discharge inpatient total 11,044 Nelson (2015)18
Post-discharge pharmacy 710 Nelson (2015)18
Cost of initiativevariable
Screening test 25 Clancy (2006),19
McKinnell (2015)20
Gloves 0.07 Nelson (2010)21
Gown 0.80 Nelson (2010)
Cost of initiativeﬁxed (per facility)
MRSA prevention coordinator
Salaryþbeneﬁts 89,679 BLS (2014)22
Laboratory technician
Salaryþbeneﬁts 65,503 BLS (2014)22
Proportion used 0.5 VA MRSA Initiative
(continued on next page)
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May 2016downward trend over time. For
total costs, the cost was $131.3
million and $155.8 million
under these assumptions.
Table 3 also shows the results
from the CEA. The ICER
ranged from $28,048/LY to
$49,435/LY when considering
total costs and $35,557/LY to
$56,944/LY when considering
variable costs only across all 3
years. Probabilistic sensitivity
analyses are presented as
cost-effectiveness acceptability
curves in Appendix Figures 4A
and 4B (available online) for the
straight-line and downward
trend assumptions, respectively.Discussion
Using published estimates of the
MRSA HAIs rates after the VA’s
MRSA Prevention Initiative,
per-patient cost of MRSA HAIs
in the VA, cost of the initiative,
and a range of estimates of what
the rate of MRSA HAIs would
have been had the initiative not
been implemented, this analysis
presents the impact of the ini-
tiative on the VA’s budget as
well as the cost effectiveness of
this intervention. Using several
different assumptions of the
number of MRSA HAIs that
occurred and would have
occurred over this 3-year period
without the initiative, the initia-
tive resulted in 1,4662,176
fewer MRSA HAIs.
Historically, the threshold for
cost effectiveness has been con-
sidered $50,000 per quality-
adjusted LY, a metric similar to
the LY metric used in this study
but that reﬂects morbidity as
well as mortality. Incorporating
the initiative’s cost as well as the
costs saved by preventing
MRSA HAIs, the model yielded
ICERs within or close to this
Table 1. Input Parameters for BIA and CEA Model (continued)
Input Value Source
Educational materials (per facility)
FY 2007 5,618 VA MRSA Initiative
FY 2008 1,082 VA MRSA Initiative
FY 2009 1,086 VA MRSA Initiative
FY 2010 1,068 VA MRSA Initiative
Time to don gloves and gown, min 2 Kang (2012)23
No. of visits by nurse per daynon-ICU 20 Morgan (2013),24
Cohen (2012),25
McArdle (2006)26
No. of visits by doctor per daynon-ICU 4 Morgan (2013), Cohen (2012),
McArdle (2006)
Effectiveness outcome (LY gained)
Mean age of patients 50 Assumption
Mean life expectancy 78.8 CDC FastStats (2015)27
Mortality
Probability of pre-discharge death
attributable to MRSA HAI
0.101 Internal VA data
Probability of post-discharge death 0.0042 U.S. SSA (2011)28
Post-discharge hazard ratio for death
attributable to MRSA HAI
1.46 Nelson (2015)29
BIA, budget impact analysis; BLS, U.S. Bureau of Labor Statistics; CEA, cost-effectiveness analysis; FY,
ﬁscal year; HAI, hospital-acquired infection; ICU, intensive care unit; LY, life-year; MRSA, methicillin-
resistant Staphylococcus aureus; SSA, Social Security Administration; VA, Department of Veterans Affairs.
Nelson et al / Am J Prev Med 2016;50(5S1):S58–S65S62threshold. Of course, it is important to note that this
analysis was done from the perspective of the VA
healthcare system and does not incorporate other per-
spectives, including the patient perspective. Future stud-
ies that extend this work by examining the patient or
societal perspectives would be valuable.
The results from this model can be useful to VA
decision makers as a way to evaluate a program that was
implemented nationwide in the largest integrated health-
care system in the U.S. BIAs are particularly useful in
integrated healthcare systems like the VA, where short-
term ﬁnancial consequences can be weighed against long-
term clinical outcomes among both providers and payers
of health care. In addition, despite the use of mostly VA-
speciﬁc input parameters, these results can be useful to
decision makers in other healthcare systems who are
considering adopting a similar strategy of universal sur-
veillance for MRSA in an inpatient setting.
Although the purpose of the current analysis was to
evaluate the universal surveillance strategy that was
implemented in the VA healthcare system, alternative
strategies in which only a subset of the patients admittedto a hospital are screened may
be more efﬁcient in terms of
healthcare resources.31 Exam-
ples of these strategies include
screening ICU patients only,23
or those with other risk factors,
such as a high number of pre-
vious healthcare encounters,
prior MRSA colonization, and
previous antibiotic therapy.32
Future economic evaluations
should compare universal and
targeted surveillance strategies.
The distinction between total
and variable costs is important.
Total costs are made up of ﬁxed
costs and variable costs. Fixed
costs in health care are those
that must be paid regardless of
how many patients are treated
or in what manner they are
treated. Variable costs, on the
other hand, are those that could
be avoided if infections are
prevented. In this paper, both
the total and variable costs of
the MRSA HAIs that were pre-
vented by the VA MRSA Pre-
vention Initiative are reported.
The variable cost results are
certainly relevant because theyrepresent the true cost savings for the VA for HAIs
prevented in the short run. The total costs results are
reported because all costs are variable over a long enough
time horizon. Therefore, the results that include the total
cost of MRSA HAIs are relevant for long-term decision
making because they include all costs that could be saved
in the long run due to a reduction of MRSA HAIs.
Though the variable cost estimates from the budget
impact model are positive, ranging from $166.4 million
to $179.5 million per year, they represent a small fraction
of the VA’s annual budget for medical care, which was
$47.4 billion in 2010.
This analysis did not include the opportunity cost of
lost bed-days, an important measure of the economic
impact of HAIs.30 This opportunity cost essentially
amounts to the value of alternative uses of the hospital
beds that are not possible when they are occupied by
patients with HAIs. Although a recent study used
contingent valuation methods to generate estimates of
the value of these bed-days from the perspective of
administrators of European hospitals, no such estimates
exist for the VA.33www.ajpmonline.org
Table 2. Aggregate Cost Savings (U.S.$) Due to VA MRSA Prevention Initiative
Pre-discharge costs Post-discharge costs Overall costs
Year Total Variable Inpatient total Inpatient variable Pharmacy Total Variable
Straight line assumption
FY2008 5,636,973 2,947,939 2,330,502 1,229,401 149,824 8,117,300 4,327,164
FY2009 19,227,002 10,055,045 7,949,047 4,193,331 511,031 27,687,080 14,759,407
FY2010 27,399,269 14,328,854 11,327,719 5,975,669 728,240 39,455,229 21,032,763
Total 52,263,245 27,331,838 21,607,268 11,398,401 1,389,095 75,259,608 40,119,334
Downward trend assumption
FY2008 3,741,700 1,956,777 1,546,936 816,050 99,450 5,388,086 2,872,277
FY2009 13,427,428 7,022,072 5,551,321 2,928,467 356,885 19,335,633 10,307,425
FY2010 18,033,768 9,431,026 7,455,727 3,933,092 479,316 25,968,810 13,843,434
Total 35,202,895 18,409,876 14,553,984 7,677,609 935,651 50,692,530 27,023,135
FY, ﬁscal year; MRSA, methicillin-resistant Staphylococcus aureus; VA, Department of Veterans Affairs.
Nelson et al / Am J Prev Med 2016;50(5S1):S58–S65 S63Though this is the ﬁrst BIA of a universal surveillance
strategy to detect and isolate patients with MRSA
colonization to reduce MRSA transmission, several
previous studies have examined the cost effectiveness of
this intervention. Using a decision analytic model, the
authors previously compared the cost effectiveness of
universal surveillance and universal surveillance plus
decolonization with a topical antibiotic with no surveil-
lance.21 Universal surveillance was found to be bothTable 3. BIA and CEA Results of VA MRSA Prevention Initiative
BIA
Difference, U.S.$
Year Total cost Variable cost
Straight line assumption
FY2008 57,847,528 61,637,664
FY2009 42,286,440 55,214,112
FY2010 31,127,782 49,550,248
Total 131,261,750 166,402,024
Downward trend assumption
FY2008 60,576,742 63,092,551
FY2009 50,637,886 59,666,094
FY2010 44,614,200 56,739,577
Total 155,828,828 179,498,223
Note: LY, ICER, interpreted as the expenses toward the VA MRSA Preventio
BIA, budget impact analysis; CEA, cost-effectiveness analysis; FY, ﬁscal year; I
resistant Staphylococcus aureus; VA, Department of Veterans Affairs.
May 2016more effective and less costly than no surveillance. This is
a slightly different result from what was found in the
current analysis (i.e., that universal surveillance results in
an overall increase in costs). The reason for this is that
the previous analysis did not include the cost of MRSA
prevention coordinators and did not include the cost of
testing on transfer and discharge. A subsequent analysis
reported by Kang et al.23 in 2012 found that universal
surveillance was more costly than no surveillance, butCEA
Incremental
LYs gained
ICER, U.S.$
Total cost Variable cost
504.8 114,605 122,114
1,721.7 24,561 32,070
2,453.4 12,687 20,196
4,679.8 28,048 35,557
335.0 180,801 188,310
1,202.3 42,116 49,625
1,614.8 27,628 35,137
3,152.2 49,435 56,944
n Initiative required to yield an additional year of patient life.
CER, incremental cost-effectiveness ratio; LY, life-year; MRSA, methicillin-
Nelson et al / Am J Prev Med 2016;50(5S1):S58–S65S64that this increased cost resulted in sufﬁciently fewer
MRSA HAIs to result in cost effectiveness.Limitations
This study had several limitations. First, assumptions were
made regarding the number MRSA HAIs that would have
occurred if the intervention had not been implemented.
There is no way of knowing what the rate of HAIs would
have been in the absence of the initiative, but several
different assumptions were explored in order to present a
range of budget impact and cost-effectiveness estimates.
Second, most of the inputs to the model were generated
using VA data. Therefore, these results may not be as
applicable in other healthcare systems. For example,
unlike private and nonproﬁt healthcare systems, which
are ﬁnanced through care provided and paid for by
patients or by third-party payers, the VA is funded
through annual congressional appropriations. The costs
saved from prevention of HAIs have different ramiﬁca-
tions based on these different ﬁnancial models. In the case
of the VA, this means less expenditure on care provided
now, which impacts budget requests in the future. For
nongovernment-funded hospitals, fewer HAIs can affect
reimbursements and, in turn, proﬁts. These different
ﬁnancial incentives may lead to different input parameters
in each step of the economic models developed here from
the effect of the intervention to the cost saved by each HAI
prevented. However, the extensive use of VA data to
parameterize the model, thus using context-speciﬁc costs
and consequences in order to evaluate an initiative that
was implemented within the VA system, is also a strength
of this study. Third, the model focused solely on MRSA
HAI prevention and costs, whereas the infection-control
interventions that comprised the MRSA Prevention Ini-
tiative may have reduced transmission of many other
pathogens that lead to HAIs, such as vancomycin-resistant
enterococcus and Clostridium difﬁcile.12 However, further
studies are necessary to examine the economic impact of
the VA MRSA Initiative on other pathogens.Conclusions
Preventing MRSA HAI can improve survival and reduce
costs among hospitalized patients. However, these pre-
vention efforts come at a cost and the overall budget
impact and cost effectiveness of the intervention depends
on how many infections can be expected to be prevented.
Using a model that explored several different assump-
tions for the rate of MRSA HAIs that would have
occurred in the VA if the MRSA Prevention Initiative
had not been implemented, the initiative was found to be
cost effective.Publication of this article has been sponsored by the Centers for
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